sacituzumab govitecan
gilead sciences
['breast', 'trodelvy', 'gilead']
after dropped an ambiguous line for #trodelvy s performance in hr-positive, her2-negative #breastcancer in march, all eyes are on this weekend's data presentation. and those detailed results don t exactly meet doctors expectations. #asco 
?? Lisbon ????????
?? #pharmaceuticals #healthcare #AI
?? Leveraging tech & data to address challenges to Patient Care & HCP engagement #CXStrategy